Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MSLN positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MSLN expression (11)

MSLN overexpression (5)

MSLN overexpression + PD-L1 overexpression (2)

MSLN expression (11)

MSLN overexpression (5)

MSLN overexpression + PD-L1 overexpression (2)

›

MSLN positive	Mesothelioma	MSLN positive	Mesothelioma	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2	TC-210 Sensitive: C2 – Inclusion Criteria TC-210 Sensitive : C2
MSLN positive	Solid Tumor	MSLN positive	Solid Tumor	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
MSLN positive	Lung Non-Small Cell Squamous Cancer	MSLN positive	Lung Non-Small Cell Squamous Cancer	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D
MSLN positive	Mesothelioma	MSLN positive	Mesothelioma	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D
MSLN positive	Pancreatic Cancer	MSLN positive	Pancreatic Cancer	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D	MSLN-CAR-T cell therapy Sensitive: D – Preclinical MSLN-CAR-T cell therapy Sensitive : D